Eli Lilly (LLY) News Today
LLY rose 0.36% in the 10 minutes after this headline crossed at 11:40:56 ET on Thursday, Oct 29:
Eli Lilly reported $303 million in asset impairment, restructuring and other special charges for the three months ended Sept. 30 in an SEC filing
Price 1363.33 two minutes before the headline, 1368.18 10 minutes after it.
Latest headline on this page:
Ask ChatGPT about LLYAsk Claude about LLYConnect MoveSurge to your assistant
Why Eli Lilly (LLY) moved: the full explanation
5 headlines on Eli Lilly appeared in our news feed in the last 7 days with a measured price reaction attached. 2 of them moved the underlying at least 0.35% in the minutes after the headline crossed. The largest measured reaction was +0.49% over 10 minutes on LLY, after the headline at Oct 29, 09:44:03 ET. 4 more headlines have no measured move.
What moved LLY — last 7 days
| Time | Headline | 1 min | Reaction |
|---|---|---|---|
| Oct 29, 11:40:56 ET | Eli Lilly reported $303 million in asset impairment, restructuring and other special charges for the three months ended Sept. 30 in an SEC filing | +0.04% | +0.36% · 10m |
| Oct 29, 09:44:03 ET | Walmart, Eli Lilly and three other companies opt out of OKX and ICE tokenized-stock plans, raising objections from more than 50% of the original roster | +0.07% | +0.49% · 10m |
| Oct 29, 07:06:43 ET | According to a presentation, Eli Lilly (LLY) says its obesity medicines are being selected by 7 out of 10 patients through the government’s Medicare programme. | — | No measured move |
| Oct 29, 06:49:54 ET | Eli Lilly Lowers FY2026 Adj EPS Guidance from $35.50-$36.50 to $35.00-$36.00 vs $34.04 Est; Raises FY2026 Sales Guidance from $85.000B-$87.000B to $91.000B-$92.000B vs $88.848B Est | — | No measured move |
| Oct 29, 06:48:17 ET | Eli Lilly and Company (LLY) Q3 2026 (USD): adj. EPS 7.48 (exp. 5.68), Revenue 24.4bln (exp. 22.58bln); Mounjaro 10.7bln (exp. 9.95bln), Zepbound 5.3bln (exp. 5bln) Current FY Rev. 91-92bln (exp. 88.82bln), adj. EPS 35-36 (prev. view 35.5-36.5, exp. 33.93) | — | No measured move |
| Oct 28, 11:44:00 ET | ADDF’s Diagnostics Accelerator licenses its longitudinal SpeechDx speech-and-biomarker dataset to Eli Lilly for Alzheimer’s research | -0.03% | -0.02% · 10m |
| Oct 28, 10:21:17 ET | Eli Lilly says experimental retatrutide delivered more than twice Ozempic’s weight loss and better blood sugar control in a diabetes study | -0.12% | -0.16% · 10m |
| Oct 28, 06:46:15 ET | In a head-to-head trial, Eli Lilly’s (LLY) retatrutide achieved a larger A1C reduction and over twice the weight loss versus Novo Nordisk’s (NOVOB DC) Ozempic at its highest approved dose. | — | No measured move |
| Oct 26, 15:59:04 ET | U.S. judge rules against Novo Nordisk, allowing Eli Lilly to continue advertising its weight-loss drugs | +0.03% | +0.03% · 10m |
Moves are measured against the price two minutes before each headline crossed, using validated 1-minute bars captured at publish time. A dash means no bar was available for that window. Reaction pending means the measuring window for that headline is still open. Not attributed means the headline does not name the company the move was measured on, so we hold the number back. Times are New York ET. Headlines appear here 1 minute after they cross the live tape.
Our analysis
How Eli Lilly Stock Reacted to Its Q2 2026 Earnings, Measured Minute by Minute
Monday, Aug 24, 2026 · Every earnings headline that crossed for Eli Lilly on 5 August 2026, with the price reaction measured from the instant each line printed.
Why Was Eli Lilly Stock Up on Aug 19, 2026?
Wednesday, Aug 19, 2026 · Lilly rose 4.46% and announced nothing. Every major drug name rose with it while the S&P 500 barely moved — and Lilly's own earnings beat measured …